The White Room
Clinical Trials E-Booklet Chapter 3: Clinical Trial Endpoints


Size: 0.01 MB (PNG)
Rating:

Clinical Trials E-Booklet Chapter 3: Clinical Trial Endpoints

Boehringer Ingelheim


Related Documents

Items: 10
Press release LUME-Lung 1+2 November 2008

Press release LUME-Lung 1+2 November 2008

Press release New Lux-Lung 1 data December 2010

Press release New Lux-Lung 1 data December 2010

Press release Lux phase 3 BIBW 2992 (afatinib)

Press release Lux phase 3 BIBW 2992 (afatinib)

Press release LUME-Ovar 1 December 2009

Press release LUME-Ovar 1 December 2009

Boehringer Ingelheim to commence Lux Lung 3 study investigating the role of BIBW 2992* as first-line treatment for non-small cell lung cancer (NSCLC) patients with EGFR mutations

Boehringer Ingelheim to commence Lux Lung 3 study investigating the role of BIBW 2992* as first-line treatment for non-small cell lung cancer (NSCLC) patients with EGFR mutations

Clinical Trials E-Booklet Chapter 5: Clinical Trial Statistics

Clinical Trials E-Booklet Chapter 5: Clinical Trial Statistics

Webcast: The Evolution of Cancer Therapies

Webcast: The Evolution of Cancer Therapies

Webcast South Korea, the evolution of lung cancer care

Webcast South Korea, the evolution of lung cancer care

Boehringer Ingelheim’s Research Facility in Vienna and Ovarian Cancer

Boehringer Ingelheim’s Research Facility in Vienna and Ovarian Cancer

BIBF 1120 in ovarian cancer

BIBF 1120 in ovarian cancer